At the Cancer Moonshot Summit, the vice president announced several new initiatives that support the program’s goals of speeding up cancer research.
Maintenance treatment with the novel agent niraparib improved progression-free survival (PFS) compared with placebo for patients with recurrent ovarian cancer harboring a germline BRCA (gBRCA) mutation or homologous recombination deficiency (HRD).
CURE recently interviewed Naveen Pemmaraju to discuss the unique aspects of the MPN community, the pitfalls of social media and the importance of patients and physicians interacting.
Cancer survivors often experience physical and psychosocial long-term and late effects after treatment ends.
Scientists are enthusiastic about new technology that will be able to edit human genes.
Testing for BRCA mutations is an important step in developing the treatment plan for patients with breast cancer, says Leslie Randall.
Two studies showed that Jakafi has high response rates with patients with GVHD, making the FDA give the drug a breakthrough therapy designation.
An Extraordinary Healer essay honoring Nancy Dodds, RN, ONC [ Hurley Medical Center in Flint, Michigan ]
An Extraordinary Healer essay honoring Corrine C. Hoeppner, MN, ARNP [Seattle Children's Hospital in Seattle, Washington]